Top

Published in:

01-05-2017 | Laboratory Investigation

IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas

Authors: Amélie Darlix, Jérémy Deverdun, Nicolas Menjot de Champfleur, Florence Castan, Sonia Zouaoui, Valérie Rigau, Michel Fabbro, Yordanka Yordanova, Emmanuelle Le Bars, Luc Bauchet, Catherine Gozé, Hugues Duffau

Published in: Journal of Neuro-Oncology | Issue 1/2017

Abstract

Diffuse low-grade gliomas (DLGG) prognosis is variable, depending on several factors, including the isocitrate dehydrogenase (IDH) mutation and the 1p19q codeletion. A few studies suggested associations between these parameters and tumor radiological characteristics including topography. Our aim was analyzing the correlations between the IDH and 1p19q statuses and the tumor intracerebral distribution (at the lobar and voxel levels), volume, and borders. We conducted a retrospective, monocentric study on a consecutive series of 198 DLGG patients. The IDH and 1p19q statuses were recorded. The pre-treatment magnetic resonance FLAIR imagings were reviewed for determination of lobar topography, tumor volume, and characterisation of tumor borders (sharp or indistinct). We conducted a voxel-based lesion-symptom mapping analysis to investigate the correlations between the IDH and 1p19q statuses and topography at the voxel level. The IDH mutation and 1p19q statuses were correlated with the tumor topography defined using lobar anatomy (p < 0.001 and p = 0.004, respectively). Frontal tumors were more frequently IDH-mutant (87.1 vs. 57.4%) and 1p19q codeleted (45.2 vs. 17.0%) than temporo-insular lesions. At the voxel level, these associations were not found. Tumors with sharp borders were more frequently IDH-mutant (p = 0.001) while tumors with indistinct borders were more frequently IDH wild-type and 1p19q non-codeleted (p < 0.001). Larger tumors at diagnosis (possibly linked to a slower growth rate) were more frequently IDH-mutant (p < 0.001). IDH wild-type, 1p19q non-codeleted temporo-insular tumors are distinct from IDH-mutant, 1p19q codeleted frontal tumors. Further studies are needed to determine whether the therapeutic strategy should be adapted to each pattern.

Available only for authorised users

Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109CrossRefPubMedPubMedCentral

Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMed

Capelle L, Fontaine D, Mandonnet E et al (2013) Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. J Neurosurg 118(6):1157–1168CrossRefPubMed

Mandonnet E, Delattre JY, Tanguy ML et al (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol 53(4):524–528CrossRefPubMed

Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372(26):2499–2508CrossRefPubMedPubMedCentral

Brat DJ, Verhaak RGW, Aldape KD et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372(26):2481–2498CrossRefPubMed

Kaloshi G, Benouaich-Amiel A, Diakite F et al (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68(21):1831–1836CrossRefPubMed

Metellus P, Coulibaly B, Colin C et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120(6):719–729CrossRefPubMed

Gozé C, Blonski M, Le Maistre G et al (2014) Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas. Neuro Oncol 16(8):1100–1109CrossRefPubMedPubMedCentral

10.

Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47(5):458–468CrossRefPubMed

11.

Ricard D, Kaloshi G, Amiel-Benouaich A et al (2007) Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann Neurol 61(5):484–490CrossRefPubMed

12.

Pignatti F, van den Bent M, Curran D et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20(8):2076–2084CrossRefPubMed

13.

Smith JS, Chang EF, Lamborn KR et al (2008) Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 26(8):1338–1345CrossRefPubMed

14.

Duffau H, Capelle L (2004) Preferential brain locations of low-grade gliomas. Cancer 100(12):2622–2626CrossRefPubMed

15.

Ren X, Cui X, Lin S et al (2012) Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients. PLoS ONE 7(3):e32764CrossRefPubMedPubMedCentral

16.

Parisot S, Darlix A, Baumann C et al (2016) A probabilistic atlas of diffuse WHO grade II glioma locations in the brain. PLoS ONE 11(1):e0144200CrossRefPubMedPubMedCentral

17.

Ius T, Angelini E, Thiebaut de Schotten M et al (2011) Evidence for potentials and limitations of brain plasticity using an atlas of functional resectability of WHO grade II gliomas: towards a “minimal common brain”. Neuroimage 56(3):992–1000CrossRefPubMed

18.

Jakola AS, Myrmel KS, Kloster R et al (2012) Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA 308(18):1881–1888CrossRefPubMed

19.

Stockhammer F, Misch M, Helms HJ et al (2012) IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure 21(3):194–197CrossRefPubMed

20.

Laigle-Donadey F, Martin-Duverneuil N, Lejeune J et al (2004) Correlations between molecular profile and radiologic pattern in oligodendroglial tumors. Neurology 63(12):2360–2362CrossRefPubMed

21.

Gozé C, Rigau V, Gibert L et al (2009) Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis? J Neurooncol 91(1):1–5CrossRefPubMed

22.

Bates E, Wilson SM, Saygin AP et al (2003) Voxel-based lesion-symptom mapping. Nat Neurosci 6(5):448–450PubMed

23.

Wang YY, Zhang T, Li SW et al (2015) Mapping p53 mutations in low-grade glioma: a voxel-based neuroimaging analysis. Am J Neuroradiol 36(1):70–76CrossRefPubMed

24.

Wang Y, Fan X, Zhang C et al (2014) Anatomical specificity of O6-methylguanine DNA methyltransferase protein expression in glioblastomas. J Neurooncol 120(2):331–337CrossRefPubMed

25.

Rorden C, Brett M (2000) Stereotaxic display of brain lesions. Behav Neurol 12:191–200CrossRefPubMed

26.

Viegas C, Moritz-Gasser S, Rigau V, Duffau H (2011) Occipital WHO grade II gliomas: oncological, surgical and functional considerations. Acta Neurochir 153(10):1907–1917CrossRefPubMed

27.

Ceccarelli M, Barthel FP, Malta TM et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164(3):550–563CrossRefPubMedPubMedCentral

28.

Zlatescu MC, Tehrani-Yazdi A, Sasaki H et al (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61(18):6713–6715PubMed

29.

Mueller W, Hartmann C, Hoffmann A et al (2002) Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 161(1):313–319CrossRefPubMedPubMedCentral

30.

Huang L, Jiang T, Yuan F et al (2008) Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors. Clin Neurol Neurosurg 110(10):1020–1024CrossRefPubMed

31.

van Thuijl HF, Scheinin I, Sie D et al (2014) Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas. Genome Biol 15(9):471–483CrossRefPubMedPubMedCentral

32.

Huse JT, Diamond EL, Wang L, Rosenblum MK (2015) Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true “oligoastrocytoma”? Acta Neuropathol 129(1):151–153CrossRefPubMed

33.

Desmurget M, Bonnetblanc F, Duffau H (2007) Contrasting acute and slow-growing lesions: a new door to brain plasticity. Brain 130(Pt 4):898–914CrossRefPubMed

34.

Jenkinson MD, du Plessis DG, Smith TS et al (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129(Pt 7):1884–1891CrossRefPubMed

35.

Megyesi JF, Kachur E, Lee DH et al (2004) Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10(13):4303–4306CrossRefPubMed

36.

Kim JW, Park CK, Park SH et al (2011) Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours. J Neurol Neurosurg Psychiatry 82(2):224–227CrossRefPubMed

Title: IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas
Authors: Amélie Darlix
Jérémy Deverdun
Nicolas Menjot de Champfleur
Florence Castan
Sonia Zouaoui
Valérie Rigau
Michel Fabbro
Yordanka Yordanova
Emmanuelle Le Bars
Luc Bauchet
Catherine Gozé
Hugues Duffau
Publication date: 01-05-2017
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2421-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report

Is there a potential role for EGFR expression to lead margin reduction in glioblastoma?

Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge

Does early resection of presumed low-grade glioma improve survival? A clinical perspective

Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis

ZEB1 expression in Chinese lower-grade gliomas